Ladenburg analyst Jeffrey Cohen believes that an 8-K filing made by ChromaDex (CDXC) on December 4 “may have been misconstrued by the market.” The Dartmouth-owned patents had been previously ruled invalid, essentially closing and concluding the arrangement between the two parties, and the agreement ensures that the company will not owe any royalties to Dartmouth, explains the analyst, who adds that the 8-K has no impact on the company’s intellectual property position, which the firm believes is “extremely strong.” Ladenburg has a Buy rating and $6.80 price target on ChromaDex shares.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CDXC:
- ChromaDex price target raised to $8 from $6 at Roth MKM
- Biotech Alert: Searches spiking for these stocks today
- ChromaDex price target raised to $8 from $6 at H.C. Wainwright
- ChromaDex Reports Strong Q3 2024 Financial Results
- Chromadex Reports Strong Q3 2024 with 31% Sales Increase
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
